# Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

> **NCT00258856** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 234 (actual)

## Conditions studied

- Meningitis
- Meningococcal Infection

## Interventions

- **BIOLOGICAL:** Polysaccharide Diphtheria Conjugate Vaccine
- **BIOLOGICAL:** Polysaccharide Diphtheria Conjugate Vaccine
- **BIOLOGICAL:** Polysaccharide Diphtheria Conjugate Vaccine
- **BIOLOGICAL:** Polysaccharide Diphtheria Conjugate Vaccine

## Key facts

- **NCT ID:** NCT00258856
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-03
- **Final completion:** 2007-11
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2014-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258856, "Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00258856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*